Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 14:6:39-47.
doi: 10.4137/BMI.S6794.

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

Katarina Stenman  1 , Pär Stattin, Hans Stenlund, Katrine Riklund, Gerhard Gröbner, Anders Bergh
Affiliations

H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples

Katarina Stenman et al. Biomark Insights. .

Abstract

A high-resolution magic angle spinning NMR spectroscopic approach is presented for evaluating the occurrence, amount and aggressiveness of cancer in human prostate tissue samples. Using this technique, key metabolites in malignant and non-malignant samples (n = 149) were identified, and patterns of their relative abundance were analyzed by multivariate statistical methods. Ratios of various metabolites - including (glycerophophorylcholine + phosphorylcholine)/creatine, myo-inositol/scyllo-inositol, scyllo-inositol/creatine, choline/creatine, and citrate/creatine - correlated with: i) for non-malignant tissue samples, the distance to the nearest tumor and its Gleason score and; ii) the fraction of tumor cells present in the sample; and iii) tumor cell proliferation (Ki67 labelling index). This NMR-based approach allows the extraction of information that could be useful for developing novel diagnostic methods for prostate cancer.

Keywords: Gleason score; HRMAS; Ki67; MRSI; inositol; prostate cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Representative 1H MAS NMR spectra of A) Non-malignant; B) 10% malignant; C) 100% malignant human prostate tissue samples obtained from a 67-year-old patient with a serum PSA of 50 and a GS 7(3 + 4) stage 3 tumor. Inserted micrographs: To distinguish malignant and non-malignant glands the sections were immuno-stained to visualize basal epithelial cells (dark) lining non-malignant glands. A) 100% non-malignant prostate tissue sample with corresponding morphology. All glands are lined with a basal cell layer and are thus non-malignant; B) Malignant prostate sample containing 10% tumor and 90% non- malignant tissue. The malignant glands, seen in the middle left constitute 10% of the whole sample and lack basal cells; C) Prostate sample containing 100% cancer. In this specimen no basal cells can be seen. Note: *Contaminant.
Figure 2.
Figure 2.
Box-Plot graph depicting the correlation between the (GPCho + PCho)/Cre metabolite ratio and the fraction of cancer tissue in the prostate samples.
See this image and copyright information in PMC

References

    1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10. - PMC - PubMed
    1. Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer. CA Cancer J Clin. 2010;60:70–98. - PubMed
    1. Chrouser KL, Lieber MM. Extended and saturation needle biopsy for the diagnosis of prostate cancer. Curr Urol Rep. 2004;5(3):226–30. - PubMed
    1. Fleshner N, Klotz L. Role of “saturation biopsy” in the detection of prostate cancer among difficult diagnostic cases. Urology. 2002;60:93–7. - PubMed
    1. Baccala AA, Moussa AS, Elbary AA, et al. Risk factors and predictors of prostate cancer in men with negative repeat saturation biopsy. Uro Today Int J. 2010;3(1)

LinkOut - more resources